This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the challenges in patient access and education that will follow the first MASH drug approval. expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes how VCTE can serve as a behavioral monitor, Roger Green reviews some changes in the podcast this year and the group begins to discuss why “liver awareness” should become an important concept.
Patient advocates Neeraj Mistry of the Fatty Liver Foundation and Jenn Leigh Jones of the Society for Sober Liver Survival join Louise Campbell and Roger Green to discuss the merging of their organizations and the impact of the new nomenclature on how patients might look at their disease.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
